Associate Editorial Director, OncLive®
Kristi Rosa joined MJH Life Sciences in 2016 and has since held several positions within the company. She helped launch the rapidly growing infectious disease news resource Contagion, strengthened the Rare Disease Report, of HCPLive, and now oversees OncLive and its flagship publication OncologyLive. Prior to working at the company, she served as lead copywriter and marketing coordinator at The Strand Theater. Email: krosa@onclive.com
ADAURA Raises Questions About Optimal Use of Adjuvant EGFR TKIs in NSCLC
February 6th 2021Over the past 2 decades, the field of EGFR-mutated non–small cell lung cancer has grown tremendously, but the influx of data and the recent regulatory approval of adjuvant osimertinib have raised several important questions to be addressed to ensure that the optimal treatment approach is utilized.
Read More
Perales Examines the Impact of COVID-19 on Recipients of Cellular Therapies for Cancer
February 6th 2021February 5, 2021 - Following stem cell transplant or treatment with CAR T-cell therapies, patients with hematologic malignancies and coronavirus disease 2019 tend to have favorable outcomes, especially if they are diagnosed in complete remission and further out from their cell infusion.
Read More
FDA Approves Umbralisib for Marginal Zone Lymphoma, Follicular Lymphoma
February 5th 2021February 5, 2021 - The FDA has granted an accelerated approval to umbralisib for the treatment of select patients with relapsed/refractory marginal zone lymphoma and relapsed/refractory follicular lymphoma.
Read More
FDA Approves Liso-Cel for Refractory Large B-Cell Lymphoma
February 5th 2021February 5, 2021 - The FDA has approved lisocabtagene maraleucel for the treatment of adult patients with certain types of large B-cell lymphoma who have not responded to, or who have relapsed after, at least 2 other types of systemic treatment.
Read More
Frontline Durvalumab Fails to Improve OS in Recurrent or Metastatic HNSCC
February 5th 2021February 5, 2021 - Durvalumab failed to improve overall survival over the EXTREME chemotherapy regimen in the frontline treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma with tumors expressed high levels of PD-L1, missing a primary end point of the phase 3 KESTREL trial.
Read More
Zotiraciclib Plus Temozolomide Shows Meaningful Efficacy in Recurrent High-Grade Gliomas
February 5th 2021February 5, 2021 - The potent CDK9 inhibitor zotiraciclib, when used in combination was temozolomide, was found to induce clinically meaningful efficacy with a tolerable safety profile in patients with recurrent, high-grade gliomas.
Read More
Gilteritinib Receives Conditional Approval in China for FLT3+ AML
February 4th 2021February 4, 2021 - The China National Medical Products Administration has granted a conditional approval to gilteritinib for use in adult patients with relapsed or refractory acute myeloid leukemia with a FLT3 mutation detected by a validated test.
Read More
Unlocking the Potential of mRNA Vaccines in the Fight Against Cancer and COVID-19
February 3rd 2021February 3, 2021 - Recent progress made with messenger RNA vaccines has led to amplified protein translation, stronger modulation of immunogenicity, and improved delivery, which has all contributed to an evolution in the application of these products in the field of cancer.
Read More
Endoxifen Showcases Antitumor Activity in Breast Cancer, Phase 2 Trial Halted
February 3rd 2021February 3, 2021 - Oral endoxifen, when delivered during the “window of opportunity” between diagnosis of breast cancer and surgery, resulted in a 74% average reduction in Ki-67 and Ki-67 levels lower than 25% at the time of surgery.
Read More
QoL, Efficacy Data Support Use of Frontline Lorlatinib as New Standard in ALK+ NSCLC
February 2nd 2021February 2, 2021 - The time to treatment deterioration for symptoms such as cough, dyspnea, and pain in the chest was found to be comparable between treatment-naïve patients with ALK-positive non–small cell lung cancer who received lorlatinib versus crizotinib.
Read More
Pembrolizumab Approaches EU Approval for Expanded Indication in Relapsed/Refractory Hodgkin Lymphoma
February 1st 2021February 1, 2020 - The European Medicines Agency’s Committee of Medicinal Products for Human Use has recommended a label expansion for pembrolizumab for use as a single agent in adult and pediatric patients aged 3 years and older with relapsed/refractory classical Hodgkin lymphoma for whom autologous stem cell transplant has failed or following at least 2 previous therapies when ASCT is not an option.
Read More
Selinexor Approaches EU Approval for Refractory Multiple Myeloma
January 30th 2021January 29, 2021 - The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for selinexor for use in combination with dexamethasone in the treatment of select adult patients with refractory multiple myeloma.
Read More
Adjuvant Osimertinib Extends DFS Irrespective of Prior Adjuvant Chemo in EGFR+ NSCLC
January 29th 2021January 29, 2021 - Adjuvant osimertinib was found to improve disease-free survival in patients with EGFR-mutated non–small cell lung cancer, irrespective of previous adjuvant chemotherapy received or disease stage.
Read More
NCCN and ACS Call for Resumption of Cancer Screening, Treatment Amidst COVID-19 Crisis
January 28th 2021January 28, 2021 - The National Comprehensive Cancer Network and the American Cancer Society are collaborating with cancer organizations nationwide to promote the resumption of cancer screening and treatment during the coronavirus disease 2019 pandemic.
Read More
Tislelizumab Prolongs Survival in Advanced, Unresectable, or Metastatic ESCC
January 28th 2021January 28, 2021 - The anti–PD-1 antibody tislelizumab was found to significantly improve overall survival compared with investigator’s choice of chemotherapy in the treatment of patients with advanced, unresectable, or metastatic esophageal squamous cell carcinoma.
Read More
Expert Panel Weighs Practice-Changing Potential of Early Data in EGFR+ NSCLC
January 28th 2021As new findings emerge in the lung cancer treatment paradigm, innovative strategies have resulted in impressive central nervous system activity and encouraging responses with acceptable tolerability.
Read More
Acalabrutinib Shows Noninferior PFS, Less Atrial Fibrillation Versus Ibrutinib in High-Risk CLL
January 26th 2021January 26, 2021 - Acalabrutinib showed noninferior progression-free survival and a significantly lower incidence of atrial fibrillation versus ibrutinib in patients with high-risk chronic lymphocytic leukemia.
Read More
Frontline Pembrolizumab Approved in Europe for Metastatic MSI-H/dMMR CRC
January 26th 2021January 26, 2021 - The European Commission has approved single-agent pembrolizumab for use in the frontline treatment of patients with metastatic microsatellite instability–high or mismatch repair deficient colorectal cancer.
Read More
Acalabrutinib Approved in Japan for Relapsed/Refractory CLL
January 25th 2021January 25, 2021 - The Japanese Ministry of Health, Labour and Welfare approved the BTK inhibitor acalabrutinib for use in adult patients with relapsed/refractory chronic lymphocytic leukemia, including small lymphocytic lymphoma
Read More
Avelumab Approved in Europe for Frontline Maintenance in Metastatic Urothelial Carcinoma
January 25th 2021January 25, 2021 - The European Commission has approved avelumab for use as a frontline maintenance option in the treatment of adult patients with locally advanced or metastatic urothelial carcinoma who did not progress after having received platinum-based chemotherapy.
Read More
Axicabtagene Ciloleucel Approved in Japan for Relapsed/Refractory LBCL
January 22nd 2021January 22, 2021 — The Japan Ministry of Health, Labour and Welfare has approved the CAR T-cell therapy axicabtagene ciloleucel for use in the treatment of adult patients with certain relapsed/refractory large B-cell lymphomas.
Read More